» Articles » PMID: 24998510

New Amphotericin B-gamma Cyclodextrin Formulation for Topical Use with Synergistic Activity Against Diverse Fungal Species and Leishmania Spp

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2014 Jul 8
PMID 24998510
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Amphotericin B (AmB) has a broad antifungal and leishmanicidal activity with low incidence of clinical resistance. Its parenteral administration has high risk of nephrotoxicity that limits its use. In order to treat cutaneous infections, AmB topical administration is a safer therapy because of the low systemic absorption of the drug across mucous membranes. Moreover, in some developing countries both fungal topical infections and cutaneous leishmaniasis are an important health problem. The aim of this work is to formulate a topical amphotericin preparation and test its in vitro antifungal (against 11 different fungal species) and antileishmanial activity. γ-Cyclodextrin (γ-CD) was chosen to solubilise AmB. Furthermore, γ-CD has shown a synergistic effect on membrane destabilization with AmB. Topical novel formulations based on AmB-CD complex have exhibited greater antifungal activity (48%, 28% and 60% higher) when compared to AmB Neo-Sensitabs(®) disks, AmB dissolved in dimethyl sulfoxide (DMSO) and Clotrimazole(®) cream, respectively. Furthermore, AmB-CD methyl cellulose gel has shown significantly higher inhibition activity on biofilm formation, larger penetration through yeast biofilms and higher fungicidal activity on biofilm cells compared to AmB dissolved in DMSO. In addition, AmB-CD gel exhibited both high in vitro leishmanicidal efficacy with wider therapeutic index (between 2 and 8-fold higher than AmB deoxycholate depending on Leishmania spp.) and also in vivo activity in an experimental model of cutaneous leishmaniasis. These results illustrate the feasibility of a topical AmB formulation easy to prepare, physicochemically stable over 6 months, safe and effective against diverse fungal and parasitic cutaneous infections.

Citing Articles

Development of amphotericin B inclusion complex formulation in dissolvable microarray patches for intravaginal delivery.

Burhanuddin H, Enggi C, Tangdilintin F, Saputra R, Putra P, Sartini S Daru. 2024; 33(1):5.

PMID: 39663291 PMC: 11635085. DOI: 10.1007/s40199-024-00546-7.


Amphotericin B Ocular Films for Fungal Keratitis and a Novel 3D-Printed Microfluidic Ocular Lens Infection Model.

Rapti C, Luciano F, Anaya B, Ramirez B, Ongoren B, Dea-Ayuela M J Fungi (Basel). 2024; 10(11).

PMID: 39590681 PMC: 11595471. DOI: 10.3390/jof10110762.


Enhancing the Topical Antibacterial Activity of Fusidic Acid via Embedding into Cinnamon Oil Nano-Lipid Carrier.

Elsewedy H, Shehata T, Genedy S, Siddiq K, Asiri B, Alshammari R Gels. 2024; 10(4).

PMID: 38667687 PMC: 11049292. DOI: 10.3390/gels10040268.


Co-Delivery of a High Dose of Amphotericin B and Itraconazole by Means of a Dry Powder Inhaler Formulation for the Treatment of Severe Fungal Pulmonary Infections.

Celi S, Fernandez-Garcia R, Afonso-Urich A, Ballesteros M, Healy A, Serrano D Pharmaceutics. 2023; 15(11).

PMID: 38004579 PMC: 10675812. DOI: 10.3390/pharmaceutics15112601.


A Theoretical Analysis of Interaction Energies and Intermolecular Interactions between Amphotericin B and Potential Bioconjugates Used in the Modification of Nanocarriers for Drug Delivery.

Cuellar J, Parada-Diaz L, Garza J, Mejia S Molecules. 2023; 28(6).

PMID: 36985646 PMC: 10055876. DOI: 10.3390/molecules28062674.